Upregulation of miR-17-3p is associated with HbF in patients with β-thalassemia and induces γ-globin expression by targeting BCL11A

Siwen Zhang, Meihuan Chen, Wantong Zhao, Junhao Zheng, Yanhong Zhang, Aixiang Lv, Jingmin Li, Hua Cao, Liangpu Xu, Hailong HuangOrphanet 2025 · DOI

Abstract

The upregulated miR-17-3p is associated with fetal hemoglobin (HbF) in patients with $\beta$-thalassemia. Although miR-17-3p does not significantly affect erythropoiesis, it promotes $\gamma$-globin expression by directly targeting BCL11A, a known repressor. These findings suggest that miR-17-3p may serve as a promising therapeutic target for the treatment of $\beta$-thalassemia.

Introduction

$\beta$-thalassemia is a hereditary blood disorder characterized by impaired $\beta$-globin chain production, leading to severe anemia. A primary therapeutic strategy involves the reactivation of fetal hemoglobin (HbF), which consists of $\alpha$-globin and $\gamma$-globin. While transcription factors like BCL11A are known to repress $\gamma$-globin expression postnatally, the microRNA (miRNA) regulators controlling these factors remain under investigation. This study explores the role of miR-17-3p in modulating BCL11A and inducing HbF production.

Methods

The study utilized a clinical cohort of 17 $\beta$-thalassemia patients and 17 healthy controls to correlate miR-17-3p levels with clinical markers. Molecular validation involved dual-luciferase reporter assays in HEK-293T cells to confirm binding between miR-17-3p and the 3’-UTR of BCL11A. Functional assays were conducted in K562 erythroleukemia cells using miR-17-3p mimics and inhibitors to assess effects on BCL11A and $\gamma$-globin protein levels, alongside phenotyping for cell proliferation and apoptosis.

Results

Clinical Correlation and Upregulation

Clinical analysis demonstrated that miR-17-3p expression was approximately 3.2-fold higher in $\beta$-thalassemia patients compared to healthy controls ($3.54 \pm 2.31$ vs. $1.11 \pm 1.03$, $P < 0.001$). Notably, miR-17-3p levels showed a strong positive correlation with HbF levels ($r = 0.686$) and were significantly elevated in patients with high HbF concentrations.

Relative expression of miR-17-3p in clinical samples. (A) Comparison between healthy controls and $\beta$-thalassemia patients. (B) Comparison between patients with low ($\le 10$ g/L) and high ($\ge 10$ g/L) HbF levels.

Molecular Mechanism

Bioinformatics and luciferase assays confirmed that miR-17-3p directly targets the 3’-UTR of BCL11A. In K562 cells, miR-17-3p mimics reduced BCL11A protein levels while simultaneously increasing $\gamma$-globin expression. Importantly, miR-17-3p overexpression did not negatively impact cell proliferation, cycle progression, or apoptosis, suggesting high specificity for hemoglobin modulation without disrupting general hematopoiesis.

Discussion

miR-17-3p acts as a "repressor of the repressor" by silencing BCL11A, thereby unlocking $\gamma$-globin production. With an Area Under the Curve (AUC) of 0.8824, miR-17-3p also shows potential as a non-invasive biomarker for disease monitoring. While these results are promising, future work must validate these mechanisms in primary human CD34+ hematopoietic stem cells and address the challenges of targeted miRNA delivery to bone marrow.

Summary updated

Abstract

The upregulated miR-17-3p is associated with HbF in patients with β-thalassemia. Although miR-17-3p does not affect erythropoiesis, it promotes γ-globin expression by targeting BCL11A, suggesting that miR-17-3p may be a promising miRNA for the treatment of β-thalassemia.
BibTeX
@inproceedings{zhang2025upregulation,
  author = {Siwen Zhang and Meihuan Chen and Wantong Zhao and Junhao Zheng and Yanhong Zhang and Aixiang Lv and Jingmin Li and Hua Cao and Liangpu Xu and Hailong Huang},
  title = {{Upregulation of miR-17-3p is associated with HbF in patients with β-thalassemia and induces γ-globin expression by targeting BCL11A}},
  booktitle = {Orphanet},
  year = {2025},
  doi = {10.1186/s13023-025-03806-0},
}
Figure